VNRX: Strong IP, new products, and global partnerships drive licensing and clinical adoption in 2026
Recent milestones include a $5M milestone opportunity, new product launches, and expansion into non-sepsis disease areas. The company leverages a strong IP portfolio, asset-light model, and global partnerships, with multiple licensing deals and clinical adoption targeted for 2026.Original document…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.